Oktay, Kutluk H.Turan, VolkanBedoschi, GiulianoGoldfarb, ShariBang, Heejung2023-03-162023-03-162023Oktay, K. H., Turan, V., Bedoschi, G., Goldfarb, S., & Bang, H. (2023). Presence of BRCA mutations and a pre-chemotherapy AMH level of < 2NG/ML strongly predict risk of amenorrhea in women with breast cancer. Fertility and Sterility, 118(4), pp. E231-E231.0015-02821556-5653https://hdl.handle.net/20.500.13055/417The likelihood of post-chemotherapy (ChT) amenorrhea is still empirically determined. Breast cancer is the most prevalent malignancy among the women of reproductive age. Our aim was to determine the predictors of amenorrhea risk post-ChT in women with breast cancer (ca). As acute amenorrhea (<12mo post-ChT) can be temporary, we used amenorrhea status 12- and 18-months post-ChT as the primary endpoint.eninfo:eu-repo/semantics/closedAccessBrca MutationsBreast CancerPre-ChemotherapyAMH LevelConference Object1184E231E231Q1WOS:000891804600558